Charles River Laboratories International, Inc. reported second-quarter 2026 financial results for the period ended June 27, 2026. The company generated revenue of $1.00 billion, a decrease of 2.7% from the prior year, with organic growth of 0.1%. GAAP diluted earnings per share were $(0.03), reflecting a $63.7 million loss on divestitures, while non-GAAP diluted EPS was $3.02. The company raised its full-year 2026 guidance, increasing revenue growth expectations by 150 basis points and non-GAAP EPS midpoint by $0.25, driven by improving demand in the Discovery and Safety Assessment segment and better-than-expected Manufacturing Solutions performance. Charles River repurchased $100 million of common stock during the quarter and completed divestitures of its CDMO and Cell Solutions businesses earlier in the year. The company operates in the pharmaceutical contract research organization (CRO) industry, providing preclinical testing, drug discovery, and development services.